Related Experiment Video

Updated: Mar 8, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

8.1K

Insulin-like growth factor binding protein-4 inhibits cell growth, migration and invasion, and downregulates COX-2

Weiwen Li1, Debin Sun1, Zhuqing Lv1

  • 1Department of Pulmonary Medicine, Lishui Central Hospital, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui Hospital of Zhejiang University, Lishui, 323000, China.

Cell Biology International
|February 3, 2017
PubMed

Insights

Insulin-like growth factor binding protein 4 (IGFBP-4) exhibits antitumor effects in lung cancer. Lower IGFBP-4 levels correlate with higher cyclooxygenase-2 (COX-2) expression and increased tumor progression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Tumor inflammatory microenvironment, involving Insulin-like Growth Factor Binding Protein 4 (IGFBP-4) and Cyclooxygenase-2 (COX-2), influences tumor progression.
  • The specific roles of IGFBP-4 in lung cancer and its impact on COX-2 expression remain largely uncharacterized.

Purpose of the Study:

  • To investigate the role of IGFBP-4 in lung cancer progression.
  • To determine the effect of IGFBP-4 on COX-2 expression in lung cancer cells.

Main Methods:

  • Analysis of IGFBP-4 and COX-2 expression in lung cancer tissues and adjacent normal tissues.
  • Assessment of IGFBP-4's effects on lung cancer cell proliferation, migration, and invasion in vitro.
  • Evaluation of IGFBP-4's impact on signaling pathways including PI3K/AKT, ERK, and CREB phosphorylation.

Main Results:

  • IGFBP-4 expression was significantly lower, while COX-2 expression was higher in lung cancer tissues compared to normal tissues.
  • IGFBP-4 suppressed lung cancer cell proliferation, migration, and invasion.
  • IGFBP-4 inhibited the phosphorylation of PI3K/AKT, ERK, and CREB signaling pathways.

Conclusions:

  • IGFBP-4 demonstrates significant antitumor effects in non-small cell lung cancer (NSCLC).
  • IGFBP-4 downregulates COX-2 production and inhibits key pro-tumorigenic signaling pathways in lung cancer cells.
Keywords:
IGF-binding protein-4LPScyclooxygenase2invasionlung cancermigration

More Related Videos

The Soft Agar Colony Formation Assay08:01

The Soft Agar Colony Formation Assay

Published on: October 27, 2014

114.1K
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.4K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.0K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.8K